Recombinant Human Hyaluronidase for Injection Approved for Market — A Classic Enzyme Opening a New Era of Subcutaneous Infusion

[Shanghai, China] Mar 31st, 2026 — China’s National Medical Products Administration (NMPA) has officially approved the marketing application for recombinant human hyaluronidase for injection, independently developed by Shanghai Bao Pharmaceutical. This approval marks a significant technological breakthrough in the field of recombinant enzyme therapeutics in China and signals the formal introduction of an important drug delivery modality—facilitated subcutaneous infusion (fSC)—into clinical practice. Through the bioprocessing optimization of a classic enzyme, this product is expected to provide patients with a more flexible, safer, and more accessible therapeutic option.

For more information, please follow this link: https://www.baopharma.com.cn/zuixinxiaoxi/49

About Shanghai Bao Pharmaceutical

Founded in 2019, Shanghai Bao Pharmaceutical Co., Ltd. is an innovative biotechnology company specializing in clinical development, synthetic biology and recombinant biologics. The company focuses on replacing traditional biochemically extracted products and upgrading validated therapies, building a diversified pipeline across high-volume subcutaneous drug delivery, autoimmune diseases and assisted reproduction. With leading chassis-cell engineering capabilities, a stable commercial manufacturing system, and an international R&D team, Bao Pharma aims to become a global frontrunner in recombinant biologics.

Forward-Looking Statement

This press release may contain forward-looking statements based on current expectations, assumptions, and projections made by the management of Shanghai Bao Pharmaceutical Co., Ltd. (“Bao Pharma”). These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such statements include, but are not limited to, descriptions of business strategies, future operational plans, R&D progress, clinical-trial outcomes, commercial prospects, and financial performance. Except as required by law or regulation, Bao Pharma undertakes no obligation to update or revise any forward-looking statement to reflect new information, future events, or other changes. This press release is for informational purposes only and does not constitute investment advice or an offer to purchase securities of the company.